← Back to headlines
Neurocrine Biosciences to Acquire Soleno Therapeutics for Hunger Disorder Drug
Neurocrine Biosciences announced its plan to acquire Soleno Therapeutics, a move that will secure a drug designed to treat a relentless hunger disorder, specifically Prader-Willi syndrome. The acquisition aims to expand Neurocrine's therapeutic portfolio.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
